<DOC>
	<DOCNO>NCT00482911</DOCNO>
	<brief_summary>RATIONALE : Lenalidomide may stop growth tumor cell block blood flow tumor . Sunitinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop divide . Giving lenalidomide together sunitinib low dos cyclophosphamide day may kill tumor cell . PURPOSE : This phase II trial study well give lenalidomide together sunitinib cyclophosphamide work treat patient stage IV eye melanoma .</brief_summary>
	<brief_title>Lenalidomide , Sunitinib , Cyclophosphamide Treating Patients With Stage IV Eye Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient stage IV ocular melanoma treat lenalidomide , sunitinib malate , low-dose metronomic cyclophosphamide . Secondary - Determine toxicity regimen patient . - Determine progression-free survival patient treat regimen . - Obtain blood , urine , tissue sample patient , easily accessible , determine effect regimen pathway think modulate regimen pre-clinical study . OUTLINE : This nonrandomized , uncontrolled , open-label study . Patients receive oral lenalidomide , oral sunitinib malate* , oral low-dose cyclophosphamide daily day 1-28 . Treatment repeat every 28 day 2 year absence disease progression unacceptable toxicity . NOTE : *Some patient receive sunitinib malate course 1 . After completion study treatment , patient follow every 3 month 2 year , every 4 month 3 year annually thereafter .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Conjunctival Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ocular melanoma Stage IV disease Measurable disease No active brain metastasis Patients brain metastasis must complete excision radiotherapy remain asymptomatic stable disease magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan ≥ 6 month PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy &gt; 3 month Granulocyte count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Creatinine ≤ 1.5 mg/dL OR creatinine clearance &gt; 60 mL/min Bilirubin ≤ 2.0 mg/dL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 10 time upper limit normal ( ULN ) Prothrombin time ( PT ) /partial thromboplastin time ( PTT ) /International Normalized Ratio ( INR ) normal Not pregnant nursing Negative pregnancy test Fertile patient must use one highly effective method contraception ( additional method ) barrier method contraception ≥ 4 week , , ≥ 4 week completion study therapy Ejection fraction normal echocardiogram No acute , critical illness , include serious untreated infection No history follow : Unstable newly diagnose angina pectoris Myocardial infarction within past 6 month New York Heart Association class IIIV heart disease Congestive heart failure Chronic obstructive lung disease require oxygen therapy Chronic uncontrollable hypertension Uncontrolled seizure activity No know human immunodeficiency virus ( HIV ) positivity No know hypersensitivity reaction thalidomide , lenalidomide , sunitinib malate , cyclophosphamide PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy At least 4 week since prior surgery , chemotherapy ( 6 week mitomycin C , nitrosoureas , carboplatin ) , hormonal therapy , radiotherapy , biological therapy No concurrent grapefruit grapefruit juice No concurrent antitumor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>metastatic intraocular melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>conjunctival melanoma</keyword>
</DOC>